Artiva Biotherapeutics, Inc. · NASDAQ:ARTV

Artiva Biotherapeutics — Investor Presentation (August 2024)

21 slides from Artiva Biotherapeutics's investor presentation, August 2024

  1. Slide 1: Artiva Biotherapeutics Corporate Presentation

    Artiva Biotherapeutics Corporate Presentation August 2024 Artiva Biotherapeutics

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, witho

  3. Slide 3: Artiva's strategy: safe and effective NK cell-based therapies for community setting

    Artiva’s strategy: To develop safe and effective NK cell-based therapies that patients and physicians can utilize in a community setting 1 “Manufacturing-first” 2 AlloNK Proposed MoA: Off-the shelf, 3 Off-the-shelf with the potential Scalable manufacturing process with NK non- genetically modified N

  4. Slide 4: Artiva: Developing allogeneic, off-the-shelf, NK cell-based therapies

    Artiva: Developing allogeneic, off-the-shelf, NK cell-based therapies for patients suffering from devastating autoimmune diseases and cancers § History: Founded in 2019 as spin out of GC Cell; San Diego based, 81 employees as of May 31, 2024 Overview § IP: Exclusive worldwide ex-APAC1 rights to NK c

  5. Slide 5: Well Positioned with Experienced Team and Scientific Advisors

    Well Positioned with Experienced Team and Scientific Advisors Management Team Fred Aslan, M.D. Chris Horan CEO CTO Jen Bush, J.D. Neha Krishnamohan COO CFO, EVP Corp Dev Thorsten Graef, M.D., Heather Raymon, Ph.D. Ph.D. CMO SVP, Research and Early Development Artiva Biotherapeutics 4

  6. Slide 6: Hypothesis: AlloNK with mAbs Drives Deep B-cell Depletion and Immune Reset

    Hypothesis: AlloNK in Combination with mAbs Has Potential to Drive Deep B-cell Depletion and Immune Reset ADCC: mAbs recruit and activate NK cells for cell killing (ADCC = antibody dependent cell-mediated cytotoxicity) • Clinical evidence of NK cells enhancing mAb activity1,2 • Most efforts to enhan

  7. Slide 7: Opportunity for Impactful Therapies in Autoimmune Disease

    Opportunity for Impactful Therapies in Autoimmune Disease Learnings from Schett’s auto-CAR-T Data Considerations 1 • Proposed MOA: B-cell depletion • “One-and-done” vs. chronic therapy driving towards a potential immune Depth of B-cell • Maintenance meds reset Depletion • Durability • Clinical impro

  8. Slide 8: AlloNK in Autoimmunity: Pursuing Similar Approach as Auto-CAR-T

    AlloNK in Autoimmunity: Pursuing Similar Approach as Auto-CAR-T Activity in SLE / LN1 1 Initial, Generalized 2 “Targeted / deeper” Lymphodepletion + B-cell depletion Immune Reset B-cell Reconstitution with Naïve Cells 110 1600 SLE 100 IIM 1200 Schett: auto-CAR-T2 90 800 IIM SLE SLE 80 400 SLE 70 200

  9. Slide 9: Similarities in Proposed MoA between Autoimmune Disease and B-NHL

    Similarities in Proposed MoA between Autoimmune Disease and B-NHL In autoimmune disease… In B-NHL… …B-cells produce auto-abs …B-cells transform to cancer B-cells found in primary lymphoid tissues (e.g., bone B-NHL lesions found in lymph nodes and often in bone marrow), and in secondary lymphoid tiss

  10. Slide 10: Peripheral B-cell Depletion Following First Cycle of AlloNK + Rituximab

    Peripheral B-cell Depletion Following First Cycle of AlloNK + Rituximab in Ongoing Phase 1/2 B-NHL Clinical Trial LD + AlloNK + RTX B-cell depletion following first cycle (combination) 1 • 45 patients with B-NHL treated in Phase 1/2 clinical trial • 16 patients in monotherapy (LD+AlloNK) and 29 pati

  11. Slide 11: High Response Rates of AlloNK with Rituximab in CAR-T Naïve Patients

    High Response Rates of AlloNK in Combination with Rituximab in all Patients Naïve to prior CAR-T in Phase 1/2 B-NHL Clinical Trial CAR-T naïve patients treated with AlloNK in combination with rituximab Prior Ongoing Response Disease Demographics Lines 3mo 6mo 9mo 12mo 15mo 18mo 21mo CR Complete Resp

  12. Slide 12: AlloNK Interim Safety Data in B-NHL Patients

    AlloNK Interim Safety Data in 45 B-NHL Patients Median Age of 68 y.o. and Median of 4 Prior Lines of Therapy One day outpatient (not hospitalized) One day inpatient (hospitalized) Each column represents one day 69% Each row represents one patient (n=45) Managed Outpatient Patient IDs shown only for

  13. Slide 13: Artiva's "Manufacturing-First" Approach

    GC Cell Facility, Seoul, Korea Artiva’s “Manufacturing-First” Approach • GC Cell has been developing the process for over a decade • High yielding, reliable process platform • Over 35 clinical AlloNK batches have been produced • Artiva’s purpose-built facility in San Diego Artiva Facility, San Diego

  14. Slide 14: AlloNK's "3 Cs" in TechOps

    AlloNK’s “3 Cs” in TechOps CMC Capacity COGS Scale today: Future scale: • Extensive experience with Clinical COGS Commercial COGS AlloNK > 35 clinical batches • Release testing performed Materials Commercial on DP from 8 donor MCB’s 1 UC unit = 50+ MCB units x 80-100+ DP vials/batch target#: • Demon

  15. Slide 15: Breadth and Versatility of AlloNK to Expand into B-cell Driven Autoimmune Diseases

    We Believe the Breadth and Versatility of AlloNK Enables the Potential to Expand into Many B-cell Driven Autoimmune Diseases Breadth: Initial Indications Versatility: Multiple mAbs • Different mAbs can target B-cells versus plasma cells • Emerging clinical data have shown differentiated activity in

  16. Slide 16: AlloNK Treatment Schedule and Design in Phase 1/1b SLE / LN Trial

    AlloNK Clinical Development: Treatment Schedule and Design in Phase 1/1b SLE / LN Trial 1 Initially, Generalized 2 Goal: “Targeted / deeper” Lymphodepletion + B-cell depletion • Enrolling patients in SLE / LN • 2-Stage Trial • Stage 1: Dose escalation • 3 initial monotherapy patients (no mAb) with o

  17. Slide 17: Expected Initial Data in 1H2025 from at Least One Ongoing Trial

    Focused Execution Leading to Expected Initial Data in 1H2025 from at Least One Ongoing Trial H1’24 H2’24 H1’25 Three initial monotherapy First Patient Dosed patients (no mAb) with Initial Safety / Activity Data in Phase 1/1b opportunity to be dosed in SLE/LN Trial combination after 6 months from eit

  18. Slide 18: AlloNK's Differentiated Approach

    AlloNK’s Differentiated Approach Drivers of commercial potential: 1 • Peripheral B-cell depletion in all 29 relapsed / refractory (R/R) B-NHL patients dosed with AlloNK + RTX1 Depth of B-cell • Observed 62% CRs in R/R aggressive B-NHL patients with AlloNK + RTX2 Depletion • Ability to combine AlloNK

  19. Slide 19: Focusing on Execution, Enrollment, and Community Access

    Focusing on Execution, Enrollment, and Community Access Artiva: Many Firsts1 Potential Enrollment Advantage 1 ü Currently Auto-CAR-T in the US is typically constrained to FACT IND allowed for any allogeneic NK accredited sites cell therapy in autoimmunity ü Off-the-shelf product in outpatient settin

  20. Slide 20: Additional Information

    Additional Information Artiva Biotherapeutics 19

  21. Slide 21: Artiva's Pipeline: Focus on AlloNK in Autoimmune Diseases and Cancer

    Artiva’s Pipeline: Focus on AlloNK in Autoimmune Diseases and Cancer Product Indication Preclinical Phase 1 Phase 2 Phase 3 Partnerships Candidate + Rituximab § SLE, LN + Obinutuzumab Artiva-funded Trials § RA § PV Investigator-Initiated AlloNK § Vasculitis (GPA/MPA) Basket Trial (1) (AB-101) § SLE

Artiva Biotherapeutics — Investor Presentation (August 2024) on 6ix